Abbott is in advanced discussions to acquire Exact Sciences, a cancer diagnostics company. A deal could be announced within days, though negotiations remain fluid and could still face delays or fall through. Exact Sciences’ shares surged nearly 25% after the news, lifting its market value above $13 billion, while Abbott’s stock slipped about 3% in afternoon trading. Abbott is reviewing potential transaction terms. Exact Sciences is best known for Cologuard, its flagship non-invasive colorectal cancer screening test. Unlike colonoscopy, which requires bowel preparation, sedation, and a hospital visit, Cologuard can be completed at home by mailing a stool sample to a laboratory for analysis.
Abbott Laboratories is in advanced discussions to acquire cancer diagnostics company Exact Sciences, as per media reports. A deal could be announced within days, though negotiations remain fluid and could still face delays or fall through, the report noted.
Abbott Laboratories is in advanced discussions to acquire cancer diagnostics company Exact Sciences, as per media reports. A deal could be announced within days, though negotiations remain fluid and could still face delays or fall through, the report noted. Exact Sciences is best known for Cologuard, its flagship non-invasive colorectal cancer screening test. Unlike colonoscopy, which requires bowel preparation, sedation and a hospital visit, Cologuard can be completed at home, with patients mailing a stool sample to a laboratory for analysis.
Авторское резюме: Abbott обсуждает покупку Exact Sciences; сделка может быть объявлена в ближайшие дни, за ней следят акции обеих компаний, а Cologuard остаётся флагманским тестом Exact Sciences.
more
Voice Of HealthCare — 2025-11-20